2H-1-Benzopyran-2-one, 3-acetyl-7-[[5-fluoro-4-(4-fluoro-2-methoxyphenyl)-2-pyrimidinyl]amino]-4-(4-morpholinyl)-

Request For Quotation
2H-1-Benzopyran-2-one, 3-acetyl-7-[[5-fluoro-4-(4-fluoro-2-methoxyphenyl)-2-pyrimidinyl]amino]-4-(4-morpholinyl)- Suppliers list
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
Company Name: TargetMol Chemicals Inc.  
Tel: 13564774135
Email: marketing@targetmol.com

2H-1-Benzopyran-2-one, 3-acetyl-7-[[5-fluoro-4-(4-fluoro-2-methoxyphenyl)-2-pyrimidinyl]amino]-4-(4-morpholinyl)- manufacturers

  • CDK9-IN-19
  • CDK9-IN-19 pictures
  • $1980.00
  • 2026-07-27
  • CAS:2479306-60-8
  • Purity:
  • Supply Ability: 10g
2H-1-Benzopyran-2-one, 3-acetyl-7-[[5-fluoro-4-(4-fluoro-2-methoxyphenyl)-2-pyrimidinyl]amino]-4-(4-morpholinyl)- Basic information
Product Name:2H-1-Benzopyran-2-one, 3-acetyl-7-[[5-fluoro-4-(4-fluoro-2-methoxyphenyl)-2-pyrimidinyl]amino]-4-(4-morpholinyl)-
Synonyms:2H-1-Benzopyran-2-one, 3-acetyl-7-[[5-fluoro-4-(4-fluoro-2-methoxyphenyl)-2-pyrimidinyl]amino]-4-(4-morpholinyl)-;CDK9-IN-19
CAS:2479306-60-8
MF:C26H22F2N4O5
MW:508.47
EINECS:
Product Categories:
Mol File:2479306-60-8.mol
2H-1-Benzopyran-2-one, 3-acetyl-7-[[5-fluoro-4-(4-fluoro-2-methoxyphenyl)-2-pyrimidinyl]amino]-4-(4-morpholinyl)- Structure
2H-1-Benzopyran-2-one, 3-acetyl-7-[[5-fluoro-4-(4-fluoro-2-methoxyphenyl)-2-pyrimidinyl]amino]-4-(4-morpholinyl)- Chemical Properties
Boiling point 682.9±65.0 °C(Predicted)
density 1.425±0.06 g/cm3(Predicted)
pka0.35±0.10(Predicted)
Safety Information
MSDS Information
2H-1-Benzopyran-2-one, 3-acetyl-7-[[5-fluoro-4-(4-fluoro-2-methoxyphenyl)-2-pyrimidinyl]amino]-4-(4-morpholinyl)- Usage And Synthesis
UsesCDK9-IN-19 is a highly potent and selective CDK9 inhibitor with an IC50 value of 2.0 nM. CDK9-IN-19 has excellent cellular antiproliferative activity, moderate pharmacokinetic property and low hERG inhibition. CDK9-IN-19 significantly induces tumour growth inhibition in an MV4-11 xenograft mice model. CDK9-IN-19 can be used for researching acute myeloid leukaemia (AML)[1].
in vivo

CDK9-IN-19 (10, 20 or 40 mg/kg; IV, for 32 days) significantly suppresses the tumour progression in MV4-11 xenograft model[1].
Pharmacokinetic Parameters of CDK9-IN-19 in ICR mice[1].

PO (30 mg/kg)IV (2 mg/kg)
T1/2 (h)NR0.23
Tmax (h)0.25-
C0 (ng/mL)-3060
Cmax (ng/mL)665-
AUC0-t (ng/mL·h)1200560
AUC0-∞ (ng/mL·h)NR561
CL (L/h/kg)-3.56
VdSS (L/kg)-0.67
F (%)14.3-
Animal Model:Female BALB/c nude mice (injected with MV4-11)[1]
Dosage:10, 20 or 40 mg/kg
Administration:IV, for 32 days
Result:Significantly suppressed the tumour progression and tumour growth inhibition (TGI) values up to 100% from days 14-32 at 40 mg/kg.
IC 50CDK9/cyclinT1: 2 nM (IC50)
References[1] Xu J, et al. Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity. Eur J Med Chem. 2020 Aug 15;200:112424. DOI:10.1016/j.ejmech.2020.112424
2H-1-Benzopyran-2-one, 3-acetyl-7-[[5-fluoro-4-(4-fluoro-2-methoxyphenyl)-2-pyrimidinyl]amino]-4-(4-morpholinyl)- Preparation Products And Raw materials
Tag:2H-1-Benzopyran-2-one, 3-acetyl-7-[[5-fluoro-4-(4-fluoro-2-methoxyphenyl)-2-pyrimidinyl]amino]-4-(4-morpholinyl)-(2479306-60-8) Related Product Information
N-(5-(difluoromethoxy)-1H-pyrazol-3-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-pyrazolo[3,4-b]pyrazin-6-amine CDK12-CCNK HETERODIMER Protein, HUMAN (SF9) CDK3-CCNE1 HETERODIMER Protein, HUMAN (SF9) OTS964 hydrochloride DRB CDK2 Protein, HUMAN (HIS)